Biogenic Monoamines
-
Subject Areas on Research
- A neuroanatomic model for depression.
- A rodent model of spontaneous stereotypy: initial characterization of developmental, environmental, and neurobiological factors.
- Approaches to identify monoamine transporter interacting proteins.
- Behavioral and neurochemical changes in folate-deficient mice.
- Cellular determinants of reduced adaptability of the aging brain: neurotransmitter utilization and cell signaling responses after MDMA lesions.
- Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile.
- Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.
- Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.
- Does neurotropin-3 have a therapeutic implication in major depression?
- Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing.
- Generation and characterization of mice lacking gastrin-releasing peptide receptor.
- Monoamine mediation of cocaine-induced hypothalamo-pituitary-adrenal activation.
- Monoamine transporter pharmacology and mutant mice.
- Monoamine transporters: from genes to behavior.
- Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene.
- Pathologic role of nitrergic neurotransmission in mood disorders.
- Persistent behavioral impairment caused by embryonic methylphenidate exposure in zebrafish.
- Persistent inward currents in spinal motoneurons and their influence on human motoneuron firing patterns.
- Plasma membrane monoamine transporters: structure, regulation and function.
- Prenatal nicotine exposure in rhesus monkeys compromises development of brainstem and cardiac monoamine pathways involved in perinatal adaptation and sudden infant death syndrome: amelioration by vitamin C.
- Reduction of spontaneous alcohol drinking and physical withdrawal by levemopamil, a novel Ca2+ channel antagonist, in rats.
- TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.